AGEN

Balstilimab (AGEN2034)

Recurrent/Metastatic Cervical Cancer

BLA Submission (Ph2 data)

Exp Date

TBD

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Balstilimab (AGEN2034) in Recurrent/Metastatic Cervical Cancer

  • ClinicalTrial.gov (NCT03104699): Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer

  • ClinicalTrial.gov (NCT03894215): Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

  • ClinicalTrial.gov (NCT03495882): Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)


WHAT IS THE NEXT CATALYST EVENT?

  • Completion of BLA Submission (initiation of rolling submission 9/18/20)


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD (rolling submission started (see 9/18/20 PR)


PRIOR DATA

PRESS RELEASE

MECHANISM OF ACTION

  • Balstilimab is a novel anti-PD-1 human monoclonal antibody that has demonstrated promising clinical benefit in second line treatment of cervical cancer.

Updated by MV

#AGEN, #Balstilimab, #AGEN2034, #anti-PD1, #PD-1, #antiPD1, #PD1, #antibody, #cervical cancer, #cancer, #recurrent cervical cancer, #metastatic cervical cancer, #metastatic cancer

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon